PSMA RLT for Oligometastatic Prostate Cancer

2 Views
Published
Amar Kishan, MD, of the University of California, Los Angeles, provides his insight on the use of PSMA RLT for oligometastatic prostate cancer. Based on his presentation from the 2025 PSMA & Beyond conference, Dr. Kishan reviews current evidence supporting the use of PSMA RLT in patients with oligometastatic disease, and reviews upcoming trials investigating PSMA RLT that are worth keeping an eye on.
Category
Oncology
Be the first to comment